×
Nektar Therapeutics EBITDA 2010-2025 | NKTR
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Nektar Therapeutics ebitda from 2010 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
View More
Nektar Therapeutics EBITDA 2010-2025 | NKTR
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Nektar Therapeutics ebitda from 2010 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company Name
Market
Cap
Chugai Pharmaceutical (CHGCY)
$76.3B
Zoetis (ZTS)
$66.2B
Takeda Pharmaceutical (TAK)
$45.9B
Daiichi Sankyo, - (DSNKY)
$45.5B
BeOne Medicines - (ONC)
$32.3B
Sandoz Group AG (SDZNY)
$25B
Summit Therapeutics (SMMT)
$19.5B
Merck (MKKGY)
$16.7B
Shionogi (SGIOY)
$14.2B
United Therapeutics (UTHR)
$13.2B
Neurocrine Biosciences (NBIX)
$13.1B
Orion OYJ (ORINY)
$11B
IPSEN (IPSEY)
$10.5B
Stevanato Group S.p.A (STVN)
$7.5B
Corcept Therapeutics (CORT)
$7.5B
Madrigal Pharmaceuticals (MDGL)
$7.4B
Grifols, S.A (GRFS)
$6.8B
Ionis Pharmaceuticals (IONS)
$6.6B
Hikma Pharmaceuticals Plc (HKMPF)
$6.2B
Ono Pharmaceutical (OPHLF)
$5.2B
Soleno Therapeutics (SLNO)
$4.4B
Hypermarcas (HYPMY)
$3.1B
Crinetics Pharmaceuticals (CRNX)
$2.9B
Catalyst Pharmaceuticals (CPRX)
$2.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.5B
NewAmsterdam Pharma (NAMS)
$2.5B
Centessa Pharmaceuticals (CNTA)
$2.1B
Ocular Therapeutix (OCUL)
$1.8B
BioCryst Pharmaceuticals (BCRX)
$1.8B
ARS Pharmaceuticals (SPRY)
$1.8B